INDIA VS CHINA FOR CAR-T
HOW TO DECIDE
India has the lowest-cost approved CAR-T in the world. China has the widest target range and most clinical trials. The right choice depends on your disease, the specific target your cancer expresses, and where you live.
analyticsAt a Glance
- check_circleIndia: NexCAR19 $30โ40K, CDSCO-approved CD19 โ best cost for B-ALL and DLBCL
- check_circleChina: BCMA, GPRC5D, CLDN18.2, dual-target, allogeneic โ best for myeloma and solid tumours
- check_circleIndia: English care, easy e-visa, 1โ6 hours from South Asia and East Africa
- check_circleChina: broadest trial portfolio but Mandarin-only, M visa complexity, higher cost
India's Strengths for CAR-T
India's primary advantage is the commercialisation of NexCAR19 โ the world's lowest-cost approved CAR-T product for CD19-positive B-cell malignancies.
Cost Leadership
NexCAR19 costs $30โ40K all-in for the treatment episode. Kymriah (the global comparator) costs $475K in the USA. No other country offers a commercially approved CAR-T product at anywhere near India's price point.
CDSCO-Approved Product
NexCAR19 has received full commercial approval from India's Central Drugs Standard Control Organisation (CDSCO) โ not a trial, not compassionate use. This means predictable access, manufacturing standards, and pharmacovigilance.
Visa and Language
Indian medical e-visa is processed online in 1โ3 business days for most South Asian and East African nationalities. All major Indian CAR-T centres operate in English. No interpreter needed for most international patients.
Geography
India is 1โ6 hours from virtually all of South Asia and East Africa โ the world's largest population of patients who cannot afford Western CAR-T pricing. No other country combines affordability with this geographic proximity.
China's Strengths for CAR-T
China leads the world in CAR-T clinical trial volume and target diversity. For diseases where CD19 does not apply, or where patients have exhausted India's scope, China is the next frontier.
Broadest Target Range
China offers CAR-T against: BCMA (myeloma), GPRC5D (myeloma), CD22 (ALL), CLDN18.2 (gastric/pancreatic), GD2 (neuroblastoma/sarcoma), mesothelin (mesothelioma), dual-target constructs, and allogeneic off-the-shelf products.
Clinical Trial Volume
China runs more CAR-T clinical trials than any other country โ including for solid tumours. Many trials enrol international patients. Patients who have exhausted approved products in India or the West may find an enrolling trial in China.
Myeloma CAR-T
Carvykti biosimilar (BCMA CAR-T) is commercially available in China. BCMA+GPRC5D dual CAR-T trials at Ruijin Hospital Shanghai offer the next generation of myeloma therapy. No BCMA CAR-T exists in India as of 2026.
Solid Tumour Trials
CLDN18.2 CAR-T for gastric and pancreatic cancer, GD2 for neuroblastoma and osteosarcoma, mesothelin for mesothelioma โ these solid tumour targets are being actively trialled in China with no equivalent in India.
Disease-by-Disease Decision Matrix: India vs China
Use this framework to match your disease and situation to the right country. CancerFax applies this logic in all case reviews.
| Disease / Situation | Recommendation | Rationale |
|---|---|---|
| B-ALL or DLBCL (first CAR-T, CD19+) | India (NexCAR19) | Lowest cost, CDSCO-approved, accessible e-visa |
| B-ALL or DLBCL (clinical trial preferred) | China or India (AIIMS/CMC trial) | China for dual-target; AIIMS/CMC for academic CD19 trial |
| CD19-negative relapse after CAR-T | China | Dual CD19+CD22 CAR-T at PUTH or SYSUCC; not available in India |
| Multiple myeloma (any line) | China | BCMA CAR-T and dual-target trials; no BCMA CAR-T in India |
| Gastric or pancreatic cancer | China | CLDN18.2 CAR-T trials at Ruijin; no solid tumour CAR-T in India |
| Neuroblastoma / osteosarcoma | China | GD2 CAR-T trials; not available in India |
| South Asian / East African patient, budget โค $50K | India | Geography, visa, cost, and English language all favour India |
| Patient requiring allogeneic (off-the-shelf) CAR-T | China | Multiple allogeneic programmes; not available in India |
CAR-T Cost Comparison: India, China, USA, Europe
All-in treatment episode cost in USD for the most commonly accessed CAR-T products by country.
CD19 CAR-T (B-ALL / DLBCL)
- India (NexCAR19)$35โ55K
- China (Kymriah biosimilar)$80โ120K
- USA (Kymriah)$475K+
- EU/UK$350K+
BCMA CAR-T (Multiple Myeloma)
- IndiaNot available
- China (carvykti biosimilar)$80K
- USA (carvykti)$465K+
- EU$350K+
India vs China: Key Numbers
- $30โ40KNexCAR19 (India) โ Lowest Approved CAR-T Cost GloballyAll-in episode cost including drug, workup, hospitalisation, and monitoring.
- ~$80KBCMA CAR-T Cost in China (Carvykti Biosimilar)Significantly lower than USA/EU and the only commercially accessible BCMA CAR-T outside Western markets.
- 10+CAR-T Targets Actively Trialled in ChinaChina trials cover CD19, CD22, BCMA, GPRC5D, CLDN18.2, GD2, mesothelin, HER2, EGFR, and dual/multi-target constructs.
- 1Commercially Approved CAR-T Target in India (CD19 only)NexCAR19 covers CD19 only. BCMA, CD22, and solid tumour CAR-T are in pipeline or not available in India.
Explore Both CAR-T Programmes in Depth
Continue with detailed guides on India's and China's CAR-T programmes, costs, and escalation pathways.
Frequently Asked Questions โ India vs China for CAR-T
Can I start in India and escalate to China if needed?
Yes โ and this is a common pathway CancerFax facilitates. Patients with CD19+ B-ALL or DLBCL begin with the more affordable NexCAR19 in India. If they relapse with CD19-negative disease or require BCMA or dual-target therapy, CancerFax coordinates escalation to Chinese centres that offer these options. Indian CAR-T discharge documentation is acceptable to Chinese centres.
Is China safe for international medical travel?
China's leading cancer centres โ Ruijin Hospital Shanghai, PUTH Beijing, SYSUCC Guangzhou โ are internationally recognised academic institutions running GCP-compliant clinical trials. International patients are routinely treated. The main practical challenges are language (Mandarin-only clinical environment, requiring interpreter) and M visa complexity. CancerFax addresses both through its coordination service.
Does CancerFax recommend one country over the other?
No single country is universally better. CancerFax's recommendation depends entirely on the case: for a patient with CD19+ B-ALL and a budget of $40,000 based in Kenya, India is the clear answer. For a patient with relapsed myeloma needing BCMA CAR-T, China is the answer. CancerFax reviews each case individually and provides a country recommendation based on disease, target, cost, and geography.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination โ travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Not Sure Whether India or China Is Right for Your Case?
CancerFax reviews your diagnosis, treatment history, and CAR-T target to recommend the most appropriate country and centre โ at no cost for initial review.
This content is for informational purposes only. Country and centre selection should be confirmed with your treating oncologist.